The problem with cancer clinical trial access in the United States has never been the science — it's been geography. Patients at NCI-designated Cancer Centers in major metropolitan areas have essentially unlimited trial options. Patients at community oncology practices two hours from the nearest academic medical center frequently have none. NCORP — the NCI Community Oncology Research Program — was specifically designed to address this disparity, connecting community hospitals and oncology practices with Phase 2 and Phase 3 trials that were previously accessible only at academic centers. Understanding how NCORP funding works matters for investigators at community sites who want to expand their trial portfolio and for patients who want to understand their access options outside of major cancer centers.
Research Notice
This article is for oncology research investigators, community cancer centers, and hospital administrators seeking NCI funding. Information about current solicitations should be verified at grants.nih.gov and cancer.gov/research.
Summary
The NCI Community Oncology Research Program (NCORP) is the NCI's nationwide network for conducting cancer clinical trials in community settings — approximately 1,400 sites in 46 states. NCORP Community Sites receive UG1 grants ($400K–$2M/year based on accrual volume) to support research infrastructure; Research Bases receive U10 grants ($10M–$50M+) to design and manage trial protocols distributed through the network. New NCORP site funding opportunity announcements are active in 2026 with approaching deadlines for application and renewal cycles. The minority/underserved track has additional funding support and priority placement in the NCI trial portfolio — NCI actively recruits minority-serving hospitals and FQHCs into NCORP.
ClinicalMetric Analysis
- NCORP accrual performance is the primary driver of funding level at renewal — sites that consistently meet accrual targets receive larger UG1 awards, and chronic under-accrual is the most common reason for non-renewal. The NCI evaluates Community Sites on accrual volume to NCI-approved protocols relative to the targets in their approved application. Sites that have built strong referral networks, invested in research coordinator infrastructure, and activated a diverse portfolio of protocols from multiple Research Bases consistently outperform those that rely on a single high-volume protocol. A credible accrual plan in the application — with documented referral sources, site-specific patient demographics, and realistic monthly enrollment projections — is reviewed as carefully as the budget justification.
- The minority/underserved Community Site track has a different competitive landscape than standard Community Site grants — NCI actively recruits these sites and provides technical assistance that standard applicants don't receive. FQHCs, minority-serving hospitals, and rural critical access hospitals with no prior NCI research history are the target institutions for the MS/U designation. NCI recognizes that these institutions lack grant-writing infrastructure and provides pre-submission consultation, draft review, and program officer mentorship that is more intensive than for standard applicants. Institutions in this category who are unaware of this technical assistance are leaving their most significant competitive advantage unused — the application should reflect an active dialogue with NCI program staff, not an independently written document.
- New investigators who want NCORP involvement should affiliate with an existing Community Site or Research Base as co-investigators — establishing a new Research Base is not a viable pathway for anyone outside the established cooperative group network. The major Research Bases (SWOG, ECOG-ACRIN, Alliance, NRG Oncology) have operated for decades with deeply embedded NCI relationships and institutional infrastructure. New Research Base competition opportunities are rare, funded at very high levels, and dominated by consortia of established institutions — not realistic targets for new investigators or single institutions. The appropriate pathway into NCORP for emerging investigators is co-investigator affiliation with an existing site's protocol portfolio, which builds the accrual track record that a future Community Site leadership application requires.
NCORP Community Site vs. Research Base: Two Different Funding Structures
NCORP operates through two complementary types of institutions, and confusing them is a common mistake when first exploring the program:
- NCORP Community Sites (UG1 grants): Hospitals, oncology practices, and health systems that enroll patients in NCI-approved clinical trials and cancer care delivery research. Community Sites receive NCI funding to support the research infrastructure — a dedicated Research Coordinator, data manager, and regulatory specialist. Annual funding runs approximately $400,000–$2M depending on accrual volume and whether the site has a minority/underserved designation. Community Sites do not design trials; they conduct them. This distinction is important for the application: reviewers are evaluating accrual capacity, patient population access, research infrastructure, and health equity commitment — not scientific novelty.
- NCORP Research Bases (U10 grants): Academic institutions and NCI cooperative groups that develop and manage the clinical trial protocols offered through the NCORP network. Research Bases handle protocol development, regulatory submissions to FDA, data management, and statistical analysis across all affiliated sites. Funding is substantially larger — $10M–$50M+ per award period — and competitions are infrequent and highly competitive. The major Research Bases (SWOG, ECOG-ACRIN, Alliance for Clinical Trials in Oncology, NRG Oncology) have operated for decades; new Research Base awards are rare.
- Minority/Underserved Community Sites: A dedicated NCORP track for sites primarily serving minority, rural, or underserved populations. These sites receive enhanced funding support and have priority access to studies designed to enroll diverse patient populations. NCI specifically recruits minority-serving hospitals, Federally Qualified Health Centers, and tribal health organizations into this track. The rationale is straightforward: trials that enroll only affluent, white, English-speaking urban populations produce data of limited generalizability, and this disparity has historically been substantial.
What NCORP Sites Actually Do Day-to-Day
- Enroll patients in Phase 2 and Phase 3 cancer prevention and treatment trials from NCI-approved Research Bases — the trial portfolio available to NCORP sites is substantial, covering nearly every tumor type and research question in the NCI-funded cooperative group system
- Conduct cancer care delivery research — studies examining how cancer care is organized, delivered, and experienced, not just what treatments are used. This includes symptom management, survivorship, healthcare utilization, and health equity studies
- Participate in cancer screening and prevention studies — lung cancer screening CT implementation, colorectal cancer screening outreach in underserved populations, chemoprevention trials
- Contribute to NCI's cancer control research agenda by enrolling patient populations that aren't represented in academic center trials, including rural patients, elderly patients, racial and ethnic minority patients, and patients with multiple comorbidities
- Submit patient data to NCI's cancer data commons and contribute biospecimens to NCI's biobanking infrastructure — NCORP-contributed samples and data are available to researchers across the cooperative group network
How to Apply for NCORP Site Funding: A Realistic Walkthrough
- Step 1 — Identify the current NCORP FOA: Search NIH Guide (grants.nih.gov/grants/guide/index.html) for the active NCORP Community Site FOA. The current announcement (RFA-CA or PAR-CA series) specifies eligibility, required documentation, deadline dates, and review criteria. Contact NCI's Cancer Therapy Evaluation Program (CTEP) directly if you can't locate the current solicitation — program officers are accessible and will answer questions from prospective applicants.
- Step 2 — Honest eligibility assessment: Your institution needs an active IRB with cancer clinical trial experience; documented history of submitting IND-related regulatory documents; access to a defined patient catchment area (typically at least 1,500 newly diagnosed cancer cases per year for a full Community Site, with lower thresholds for minority/underserved track); and research coordination infrastructure or a plan to build it. Sites that have never run a clinical trial are eligible to apply but will face a steeper review process — demonstrating a history of successful trial conduct, even if modest, is helpful.
- Step 3 — Contact a Research Base before writing anything: Community Sites join NCORP through affiliation with a Research Base — not independently. Which Research Base you affiliate with depends largely on geography, institutional relationships, and sometimes tumor type specialty. Contact the NCORP program staff of Research Bases operating in your region before submitting; this relationship needs to be established before the application, and Research Bases can provide crucial guidance on the application process and site expectations.
- Step 4 — Application structure: NCORP applications follow the standard NIH Research Plan format. The core sections reviewers weight most heavily: Specific Aims (what accrual targets you're committing to, how you'll meet them); Research Strategy (detailed accrual capacity analysis by tumor type, patient population demographics, research infrastructure, health equity commitment, and how you'll maintain or grow accrual over the award period); Human Subjects; Budget; and institutional letters of support demonstrating commitment at the hospital administration level, not just the principal investigator level.
- Step 5 — Submission through Grants.gov/eRA Commons: NCORP applications submit through standard NIH systems. New Community Site application deadlines are typically in spring (for review in fall) and fall (for review in spring). Renewal applications have the same cycle but require a more detailed performance report from the current award period. Check the active FOA for exact dates — they shift slightly each cycle.
Other NCI Community Oncology Funding Mechanisms
- NCI P30 Cancer Center Support Grants (CCSGs): Comprehensive Cancer Center designations requiring substantial cancer research, training, and community outreach programs. The 71 NCI-designated centers (51 Comprehensive, 18 Cancer Centers, 2 Basic Laboratory Cancer Centers as of 2026) receive $3M–$10M+ per year for core infrastructure. P30 competitions are highly competitive — most institutions spend years building the research infrastructure required to be competitive for designation.
- NCI R37 MERIT Award: Extended funding for highly meritorious R01s — provides 5-year funding rather than the standard 2–3 year period. Awarded at initial review, not by separate application. Relevant if your institution has established NCI-funded investigators seeking funding security for ongoing trial programs.
- NCI Cancer Control R01: Standard R01 mechanism for cancer control, screening, prevention, survivorship, and health equity research. Follows standard R01 due dates (June 5, October 5, February 5). More accessible to institutions building toward NCORP eligibility or targeting research questions that don't require NCORP infrastructure.